RxDoctor Payments Data

Nicolo Cabrera, MD

Infectious Disease · Saint Louis, MONPI 1366858797

Payments from drug & device makers

$1,069in general payments, 2019–2025

Across 38 payments — averaging $28.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$429
  • Gilead$225
  • Merck$134
  • Paratek Pharmaceuticals, Inc.$133
  • Tetraphase Pharmaceuticals, Inc.$69
  • AbbVie$64
  • plus $16 from 1 others

What the payments were for

  • Food & beverage$82677%
  • Education$24323%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,069 in reported general payments places this provider in the 65th percentile of 177 infectious disease providers in Missouri.

See all infectious disease providers in Missouri

Medicare billing

Part B allowed, 2024
$40,965
Medicare patients
174
Services billed
354

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SivextroTedizolid Phosphate32$405,036
NuzyraOmadacycline Tosylate12$165,131
DalvanceDalbavancin Hcl13$63,204
Daptomycin66$17,535
Imipenem-Cilastatin SodiumImipenem/Cilastatin Sodium50$15,108
Cefepime Hcl49$8,267
MicafunginMicafungin Sodium29$5,987
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam14$3,715
CeftriaxoneCeftriaxone Sodium61$2,733
Vancomycin Hcl35$2,395
Doxycycline Hyclate69$2,358
Cefadroxil46$2,152
Minocycline Hcl40$1,754
Cefazolin Sodium23$1,631
Ciprofloxacin Hcl36$1,397

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckSivextro$134$405,03632 claims
Paratek Pharmaceuticals, Inc.Nuzyra$133$165,13112 claims
AbbVieDalvance$64$63,20413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 177 infectious disease providers in Missouri.

Other infectious disease in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →